Europe’s TCR Therapy Scene Gains Traction with €40M Series B
Swedish firm Anocca's fundraising is the first major venture capital round to go to a…
Swedish firm Anocca's fundraising is the first major venture capital round to go to a…
The Dutch startup Neogene Therapeutics has become the second T-cell therapy developer to raise a…
With the help of a huge €66M Series A round last week, the German startup…
The German biotech Immatics will partner with GSK and could receive more than €1B from…
The cancer vaccine developer Ervaxx has licensed a preclinical-stage ‘universal’ cancer immunotherapy based on the…
An international research team has found a new type of T-cell that could lead to…
The UK biotech Adaptimmune Therapeutics has inked a deal worth up to €806M with Japanese…
The field of immuno-oncology promises to make anti-cancer treatments more effective than ever. But in…
In the process of studying HIV-infected patients who naturally don’t need therapy to…
Medigene and bluebird bio are increasing the number of cancer targets against which to develop TCR…
BioNTech will dedicate its huge fundraising to develop personalized cancer immunotherapies using CAR-T, TCR and…
Scientists at Cardiff University have used CRISPR/Cas9 genome editing technology to produce highly specific killer T…